A case of hormone-refractory prostate cancer (HRPC) with tumor fever responding to docetaxel plus prednisolone therapy

We have experienced a patient with tumor fever from hormone-refractory prostate cancer (HRPC) who was treated successfully using docetaxel plus prednisolone therapy. A 65-year-old male was diagnosed with prostate cancer (T4 N1 M1b). He received androgen-ablation therapy. But six months later he was confirmed to show failure of the previous hormone therapy and disease progression even after anti-androgen withdrawal. Then docetaxel plus prednisolone therapy was started. After two courses of this therapy, the PSA level decreased by 50% or more, and after ten courses an improvement was seen on the bone scan. The patient has survived for twelve months after starting docetaxel plus prednisolone therapy, without serious adverse events.